Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer

NCT00294996 is registered in ClinicalTrials.gov with Sopherion Therapeutics as lead sponsor.

NCT NCT00294996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00294996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer
Lead sponsor
Sopherion Therapeutics
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2006
Completion date
Not reported
Enrollment
363 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer